```html

Ferroportin Disease – A Complete Patient‑Friendly Guide

Overview

Ferroportin disease (FD), also known as type 4 hereditary haemochromatosis or ferroportin‑related iron overload, is a rare genetic disorder that disrupts the normal regulation of iron export from cells into the bloodstream. The condition is caused by mutations in the SLC40A1 gene, which encodes ferroportin—the only known cellular iron exporter.

• Who it affects: Both males and females can inherit the disorder, but clinical presentation often differs by sex because women lose iron through menstruation and pregnancy.
• Prevalence: Worldwide prevalence is estimated at 1 in 200,000–250,000 individuals, making it the *second most common* hereditary iron‑overload disorder after HFE‑related haemochromatosis (source: Mayo Clinic; NIH Genetic and Rare Diseases Information Center, 2023).
• Inheritance pattern: Autosomal dominant. A single mutated copy of SLC40A1 can cause disease, and the severity varies with the specific mutation (loss‑of‑function vs. gain‑of‑function).

Symptoms

Symptoms often appear in adulthood (30‑50 years) but can surface earlier in families with “classic” loss‑of‑function mutations. The clinical picture ranges from mild iron‑store elevation to overt organ damage.

Common early signs

• Fatigue & weakness – Result from iron‑induced oxidative stress on muscle and mitochondria.
• Abdominal discomfort – Hepatomegaly (enlarged liver) may cause a dull right‑upper‑quadrant ache.
• Joint pain – Especially in the hands, knees, and hips; iron deposition in synovial tissue can mimic arthritis.
• Skin hyperpigmentation – A bronzing or gray‑blue hue, more common in males.

Organ‑specific manifestations (usually later)

• Liver: Cirrhosis, elevated transaminases, portal hypertension, or hepatocellular carcinoma.
• Heart: Cardiomyopathy, arrhythmias, or congestive heart failure.
• Endocrine glands: Diabetes mellitus, hypothyroidism, or hypogonadism.
• Pancreas: Exocrine insufficiency, leading to steatorrhea.
• Reproductive system: Early menarche or amenorrhea in women; erectile dysfunction in men.

Unique features of ferroportin disease

• Upper‑body macrocytosis – Larger red blood cells (MCV > 100 fL) without anemia in many patients.
• Low transferrin saturation despite high ferritin – A hallmark that helps differentiate FD from HFE haemochromatosis.

Causes and Risk Factors

The root cause is a mutation in the SLC40A1 gene located on chromosome 2q33.3. Over 150 distinct variants have been reported, broadly grouped into two functional classes.

Genetic mechanisms

• Loss‑of‑function (LOF) mutations – Reduce ferroportin activity, causing iron to accumulate inside macrophages and enterocytes. This pattern often presents with mildly elevated ferritin, normal or low transferrin saturation, and prominent macrophage iron deposition.
• Gain‑of‑function (GOF) or “dominant‑negative” mutations – Produce a ferroportin protein that is resistant to hepcidin regulation, leading to uncontrolled iron release into plasma. This mimics classic haemochromatosis with high transferrin saturation and rapid hepatic iron overload.

Risk factors beyond the mutation

• Family history of iron‑overload disorders.
• Co‑existing conditions that increase iron absorption (e.g., chronic hemolysis, thalassemia, excessive dietary iron or vitamin C intake).
• Alcohol use – synergistically worsens liver injury.
• Obesity and metabolic syndrome – may accelerate ferritin rise.

Diagnosis

Because symptoms overlap with other iron‑overload diseases, a systematic approach is essential.

Step‑by‑step diagnostic algorithm

1. Clinical history & physical exam – Assess family history, dietary habits, alcohol use, and look for skin hyperpigmentation or hepatomegaly.
2. Laboratory screening
   • Serum ferritin (elevated in > 80 % of cases).
   • Transferrin saturation (TSAT). In LOF FD, TSAT may be < 45 %; in GOF FD, TSAT often > 50 %.
   • Liver enzymes (ALT, AST, GGT), fasting glucose, HbA1c, and thyroid panel to screen for end‑organ damage.
3. Genetic testing – Targeted sequencing of SLC40A1 is the definitive test. Commercial panels for hereditary haemochromatosis often include this gene. A positive result confirms the diagnosis and guides family counseling.
4. Imaging
   • Magnetic resonance imaging (MRI) with T2* or R2* sequences to quantify hepatic iron concentration (HIC) non‑invasively.
   • Ultrasound or MRI elastography if cirrhosis is suspected.
5. Liver biopsy (rarely needed) – Reserved for ambiguous cases or when concurrent liver disease (e.g., NAFLD, viral hepatitis) must be ruled out.

Key diagnostic clue: High ferritin **plus** relatively low or normal TSAT points toward ferroportin loss‑of‑function variants, whereas high ferritin **plus** high TSAT suggests gain‑of‑function or classic HFE haemochromatosis.

Treatment Options

Therapy aims to reduce iron stores, prevent organ damage, and manage complications. Treatment is individualized according to mutation type, iron burden, and organ involvement.

Phlebotomy (therapeutic blood removal)

• First‑line for most symptomatic patients, especially those with GOF mutations.
• Typical schedule: 500 mL weekly until ferritin < 50 µg/L, then maintenance 5‑10 mL every 1‑3 months.
• Contraindications: anemia (Hb < 12 g/dL in women, < 13 g/dL in men), severe cardiac disease, or pregnancy.

Iron‑chelating agents

• Used when phlebotomy is not tolerated (e.g., anemia, poor venous access) or in LOF variants where iron is trapped mainly in macrophages.
• Common drugs:
  • Deferasirox (Exjade/Jadenu) – oral, 20‑30 mg/kg/d; monitor renal and hepatic function.
  • Deferoxamine (Desferal) – subcutaneous infusion 20‑40 mg/kg/d; requires pump.
  • Deferiprone (Ferriprox) – oral, 75‑100 mg/kg/d; watch for neutropenia.
• Goal: reduce ferritin to < 300 µg/L and maintain TSAT < 45 %.

Adjunctive therapies

• Vitamin C restriction – High doses increase intestinal iron absorption; keep intake ≤ 200 mg/day.
• Alcohol moderation – Limit to ≤ 1 drink/day for women and ≤ 2 drinks/day for men to protect the liver.
• Management of comorbidities – Diabetes, hypothyroidism, or heart failure should be treated per standard guidelines (American Diabetes Association, ACC/AHA).

Experimental & future therapies

• Hepcidin analogues (e.g., PT-125, lusutrombopag) – Under investigation to restore hepcidin‑ferroportin regulation, particularly for GOF mutations.
• Gene‑editing approaches (CRISPR‑Cas9) – Early‑phase trials aim to correct pathogenic SLC40A1 variants.

Living with Ferroportin Disease

While the disease is chronic, many patients lead active, healthy lives with proper monitoring.

Daily management checklist

• Track phlebotomy or chelator schedule in a health app.
• Check ferritin and TSAT every 3‑6 months (more often during the loading phase).
• Maintain a balanced diet: limit red meat, fortified cereals, and iron‑rich supplements; emphasize fruits, vegetables, whole grains, and lean poultry.
• Stay hydrated (≥ 2 L/day) to support renal clearance of chelated iron.
• Exercise regularly (150 min moderate activity per week) to improve cardiovascular health.
• Vaccinate against hepatitis A and B if liver disease is present.
• Inform all health‑care providers (dentists, surgeons) of your iron‑overload status and current treatment.

Psychosocial support

Living with a hereditary condition can cause anxiety. Consider:

• Genetic counseling for you and family members.
• Support groups (e.g., Iron Overload Support Network).
• Professional mental‑health services if you experience depression or chronic stress.

Prevention

Because FD is genetic, primary prevention is not possible for affected individuals. However, secondary prevention—reducing iron accumulation and organ damage—is achievable.

• Family screening: First‑degree relatives should undergo ferritin/TSAT testing and, if abnormal, targeted SLC40A1 sequencing.
• Dietary moderation: Avoid excessive iron supplements, iron‑fortified infant formulas (unless prescribed), and high‑dose vitamin C with meals.
• Alcohol control: Limit intake; abstain if liver fibrosis is already present.
• Regular medical follow‑up: Annual liver imaging and cardiac evaluation for those with moderate‑to‑severe iron load.

Complications

If left untreated or poorly managed, iron overload can damage multiple organs.

Complication	Typical onset	Key warning signs
Hepatic cirrhosis	10–20 years after iron excess	Ascites, jaundice, spider angiomata
Hepatocellular carcinoma	Often after cirrhosis	Unexplained weight loss, abdominal mass, elevated AFP
Cardiomyopathy/arrhythmia	Decades of iron buildup	Dyspnea, palpitations, syncopal episodes
Diabetes mellitus (bronze diabetes)	20–30 years	Polyuria, polydipsia, fasting glucose > 126 mg/dL
Hypothyroidism	Variable	Fatigue, cold intolerance, weight gain
Joint arthropathy	Mid‑life	Chronic joint stiffness, reduced range of motion

When to Seek Emergency Care

---

References: Mayo Clinic. “Hereditary Hemochromatosis.” 2023; NIH Genetic and Rare Diseases Information Center. “Ferroportin Disease.” 2023; Cleveland Clinic. “Iron Overload Disorders.” 2022; World Health Organization. “Guidelines for the Management of Iron‑Related Disorders.” 2021; American College of Cardiology. “Management of Cardiomyopathy.” 2022.

```